Reference : Pharma clinics. Le medicament du mois. Le clopidogrel (Plavix).
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/12210
Pharma clinics. Le medicament du mois. Le clopidogrel (Plavix).
French
[fr] Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
2001
Revue Médicale de Liège
Hopital de Baviere
56
3
186-9
Yes (verified by ORBi)
National
0370-629X
Liège
Belgique
[en] Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Arteriosclerosis/complications ; Aspirin/therapeutic use ; Coronary Disease/prevention & control ; Drug Therapy, Combination ; Humans ; Myocardial Ischemia/prevention & control ; Peripheral Vascular Diseases/prevention & control ; Platelet Aggregation Inhibitors/pharmacology/therapeutic use ; Randomized Controlled Trials as Topic ; Stroke/prevention & control ; Ticlopidine/analogs & derivatives/pharmacology/therapeutic use
[en] Clopidogrel is launched in Belgium by Sanofi-Synthelabo and Bristol-Myers Squibb under the trade name of Plavix. It is a potent and irreversible ADP receptor antagonist that proved to be more effective than aspirin as antiplatelet agent in the multicentre, randomised double-blind CAPRIE study. It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease. Furthermore, recent studies demonstrated that the combination of clopidogrel with aspirin is more effective than aspirin alone and better tolerated than the combination ticlopidine-aspirin for the prevention of atherothrombosis after placement of intravascular stents. Ongoing trials are evaluating the efficacy and safety of such clopidogrel-aspirin combination after acute ischaemic coronary events or in patients at very high risk of stroke. Thus the indications of clopidogrel may become even larger in a next future.
http://hdl.handle.net/2268/12210

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.